Drug intelligence / Profile preview

lisuride

Development stage
Phase 3
Lead developer
Teva Pharmaceutical Industries
Modality
Small Molecules
Administration
Oral, Subcutaneous, Transdermal
01

Overview

Lisuride is a small molecule ergot derivative of the ergoline family, used primarily as an antiparkinsonian agent, for migraine prophylaxis, and to treat conditions associated with high prolactin levels such as hyperprolactinaemia and acromegaly. It acts mainly as an agonist at dopamine D2 receptors and several serotonin receptors (notably 5‑HT1A, 5‑HT2A/2C), with additional antagonist activity at dopamine D1 and histamine H1 receptors. Its dopaminergic activity underlies its use in Parkinson’s disease and prolactin suppression, while serotonergic effects contribute to migraine prevention. Unlike some other ergot derivatives, lisuride does not cause psychedelic effects due to its strong 5‑HT1A agonism counteracting 5‑HT2A-mediated hallucinogenic pathways[1][2][3][6]. It is not approved in the United States but is marketed in various countries under multiple brand names.

Brand names
DoperginArolacCuvalitDipergonDopergineLysenyl ForteProlacamRevanil
Other names
LisuridaLisuridumLysuridLysuride Hydrogen MaleateMethylergol Carbamide
02

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)DRD2 (Dopamine D2 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)DRD1 (Dopamine D1 Receptor)

Beyond the preview

Go deeper on lisuride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lisuride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call